LYMErix

LYMErix

Public health A Lyme vaccine comprised of lipidated recombinant OspA–outer surface protein A of Borrelia burgdorferi.
Mentioned in ?
References in periodicals archive ?
These same individuals acquired patents for vaccines, such as LYMErix, that failed to become routine preventive public health measures.
8,9) Both ImmuLyme and LYMErix exhibited moderate efficacy (49%-68%) in the first year with high efficacy (83%-92%) following a booster dose.
Lymerix, developed to prevent Lyme disease, is the only vaccine ever licensed in the United States to prevent a tickborne disease in humans, but it was removed from the market during 2003 amidst poor sales and unsubstantiated reports of increased adverse events (16,17).
Less than a year after GSK introduced LYMErix in 1999, attorneys claimed the adult Lyme Disease vaccine caused arthritis.
Steere, then chief of rheumatology and immunology at Tufts School of Medicine, led the development of Lymerix, which proved 78 percent effective but had questionable long-term effects.
Antibiotics are effective during early stages of the disease, and a vaccine called LYMErix is now available.
Antibiotics are effective during early stages of the disease, and last year the FDA licensed LYMErix, the first vaccine against Lyme disease.
Lackluster demand has forced GlaxoSmithKline, maker of LYMErix, to pull the Lyme disease vaccine off the market.
The Food and Drug Administration approved LYMErix in 1998, and hundreds of thousands received the vaccine the following year.
The Food and Drug Administration has approved an enzyme-linked immunosorbent assay for detecting Lyme disease antibodies that does not yield false-positive results in those patients who have already been vaccinated with the Lymerix vaccine.
The company says the test has near Western blot accuracy in an ELISA, has no reactivity with Lymerix Lyme vaccine sera, is more sensitive in detection of antibodies in early and late Lyme disease than other kits, and eliminates the majority of other ELISA's false positives at the screening step.
A new vaccine, called LYMErix, helps protect against Lyme disease, although it is only 76 percent effective and requires three separate shots and follow-up boosters.